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Background   Teriparatide (parathyreoid hormone; PTH 1-34) 
increases skeletal mass in humans and improves fracture heal-
ing in animals. A recent randomized multicenter trial of nonoper-
ated distal radial fractures showed a moderate shortening of the 
time to restoration of cortical continuity by treatment with 20 µg 
(low-dose) teriparatide per day, but not with 40 µg (high-dose). As 
radiographic cortical continuity appears late in the healing pro-
cess, perhaps too late for clinical relevance, we studied the quali-
tative appearance of the callus 5 weeks after fracture. 
Methods   One third of the patients of the international trial 
were treated at Linköping University Hospital. The multicenter 
trial did not evaluate early callus formation. We therefore made 
a blinded qualitative scoring of the callus at 5 weeks in our 27 
patients. Callus formation was arbitrarily classified as rich, inter-
mediate, or poor. 
Results   9 patients were classified as rich (none had received 
placebo, 3 low-dose teriparatide, and 6 high-dose teriparatide). 9 
patients were classified as intermediate (1 had received placebo, 
5 low-dose, and 3 high-dose). 9 patients were classified as poor (7 
had received placebo, 1 low-dose, and 1 high-dose) (p < 0.001). 
Interpretation   This is a post hoc subgroup analysis of an out-
come variable, which was not in the official protocol. The results 
must therefore be interpreted with caution. However, in combi-
nation with the results of the larger trial, the data suggest that 
radiographic quality at an early time point might be a sensitive 
variable, perhaps better than time to cortical continuity. More-
over, teriparatide appeared to improve early callus formation in 
distal radial fractures. 

Based on animal and clinical data, there have been high expec-
tations that intermittent treatment with parathyroid hormone 
(PTH) would be efficient for acceleration of fracture heal-
ing (Chalidis et al. 2007, Skripitz and Aspenberg 2004). Low 
intermittent doses, given over more than a year, increase bone 
density and reduce fracture risk in humans. However, the doses 
used in animals for fracture healing studies have been higher 
than what can be given to humans. On the other hand, animal 
data suggest that fracture healing responds more strongly to 
PTH than does bone density (Skripitz et al. 2000).
In a recent randomized trial, teriparatide (PTH 1-34) was 
tested in nonoperatively treated distal radial fractures (Aspen-
berg 2009). The study compared placebo, teriparatide 20 µg, 
and teriparatide 40 µg, given for 8 weeks. The patients were 
radiographed regularly, and the primary endpoint was time to 
cortical continuity in 3 of the 4 visible contours of the volar 
and radial projections. The main hypothesis was that 40 µg 
would shorten the time to continuity, and the lower dose was 
only to be tested if that were the case. No effect of 40 µg terip-
aratide was found. Even so, all 3 groups were still compared 
and found to show significant differences; 20 µg teriparatide 
appeared to have shortened the time to cortical continuity by 
2 weeks (p = 0.006).
During the planning of this study, it was debated whether we 
should use estimations of a variable at a single time point or 
whether time to a certain event should be used. This issue has 
been discussed recently at conferences designed to work out 
guidelines for such clinical trials, but no consensus has been 
reached (Goldhahn et al. 2008). It was decided to do the trial 
as in the study described above. However, in Linköping we 
were in any case eager to study a rather early single time point. 
This was not because we were convinced that this would have 
greater statistical strength, but rather that it would have more 
clinical relevance.
As it turned out, the local sub-study in Linköping gave a 
clear-cut positive result, and as it could not be included in the 
report of the large trial, it is reported here separately. Acta Orthopaedica 2010; 81 (2): 234–236  235
Patients and methods
27 women were included at the Linköping study site. All 
were over 50 years of age (median 64, maximum 80), with 
minimal or no other health problems and a dorsally dislo-
cated distal radial fracture that had required closed reduction 
but was deemed appropriate for nonoperative treatment. No 
strict  radiographic  inclusion  criteria  were  defined,  as  this 
was dependent on clinical traditions of the different study 
sites,  and  the  choice  of  nonoperative  treatment  should  be 
based on the clinical situation rather than on radiographs. In 
Linköping, included patients had a pre-reduction dorsal angle 
roughly between 5 and 30 degrees and discontinuities of the 
radial joint surface of less than 2 mm. Main exclusion criteria 
were: concomitant injury, previous wrist fracture, malignant 
neoplasm during the previous 5 years, liver disease, high cal-
cium levels, joint disease, or a disease affecting bone metabo-
lism (Aspenberg et al. 2009). The protocol for the multicenter 
study was followed rigorously. No patient was lost to follow-
up. A site visit by the Swedish Medial Agency gave a good 
report.
Our  evaluation  was  done  after  the  last  patient  had  been 
included, during the postoperative year, which had to pass 
before  unblinding. After  looking  at  series  of  digital  radio-
graphs for a number of patients, we decided only to use the 
pre-reduction images and those at the 5-week follow-up. We 
asked ourselves: “Assuming that PTH has a positive effect on 
fracture healing, do we think this patient received PTH?” and 
answered yes or no. After we had categorized all 27 patients, 
we went back and tried to describe the criteria that we had 
used. 
This description was as follows. We (the authors) tried to 
get a general impression of the amount and density of callus, 
relative to what should be expected for that fracture type. We 
started with the lateral projection. In most cases, there is a 
sharp angle in the dorsal cortical contour at the fracture. At 
this angle there is usually an external callus. Most of our inter-
est was focused on this callus. If absent, the case was rated as 
“placebo”. If there was a large or dense callus, it was rated as 
“PTH”. In cases of uncertainty, we looked for callus in other 
areas, i.e. at the volar cortex or at the sides in the anteroposte-
rior projection. We paid no attention to the fracture line or to 
cortical continuity. We sometimes discussed the appearance of 
the cancellous bone, but generally concluded that this should 
not be included in the judgement. Fractures with little dislo-
cation were expected to produce smaller external callus. In 
these cases, we looked more at callus density than at its size. 
We looked at the radiographs together and made consensus 
decisions.
We repeated the rating procedure 3 days later without seeing 
the previous results. 2 patients differed in rating between these 
time points. This latter rating was regarded as the definitive 
one and was reported to the sponsor who, at this time, did not 
inform us about whether or not the rating had been successful.
After the official outcome of the entire multicenter study 
was clear, but while we were still blinded, we were asked to 
do the same rating for all patients from all sites. This was not 
possible, however, because many patients at the other sites 
had had their 5-week radiographs taken before the plaster was 
taken off, and the images could not be evaluated. We therefore 
rated only the patients from Linköping again, almost a year 
after the first rating. This time, we rated the callus as rich, 
intermediate, or poor. 
Results
Rating
In the first rating, we were able to judge from the 5-week 
radiographs which patients had received PTH (p = 0.03; Table 
1).
The second rating correlated with treatment (Spearman’s 
coefficient rs 0.662 (95% CI: 0.376–0.832) p < 0.001). 9 cases 
were classified as having rich callus. All of them had been 
treated with PTH. In contrast, none of the placebo patients 
were classified as having rich callus (Table 2). 
To  estimate  reproducibility,  the  second  rating  was  later 
dichotomized to “placebo” or “PTH” (the latter comprising 
intermediate and rich callus). The first and second ratings then 
showed agreement in 23 of the 27 patients.
 
Comparison with time to cortical continuity.
The second rating was compared with the data for time to 
cortical  continuity  from  the  multicenter  study  (3  out  of  4 
cortices). There was a correlation between time to continu-
ity in Linköping and teriparatide dose (0, 20, or 40 µg) with 
a Spearman’s coefficient rs of 0.43 (95% CI: 0.063–0.70 p = 
0.024). Dividing the times in tertiles gave rs = 0.413 (95% 
Table 1. First rating
Guess   Treatment
  Placebo   PTH  
Placebo   6   5 
PTH   2   14 
Table 2. Second rating
Rating   Treatment
  Placebo   20 µg PTH   40 µg PTH
Poor   7   1   1
Intermediate   1   5   3
Rich   0   3   6236  Acta Orthopaedica 2010; 81 (2): 234–236
CI: 0.039–0.686) p = 0.032). Remarkably, there was no strong 
correlation between the two radiological methods: rs = 0.410 
(95% CI: 0.036–0.684) p = 0.034. 
 
Discussion 
How much can an analysis of a subgroup outside the proto-
col be trusted? We believe that the 5-week classification of 
patients  was  trustworthy.  We  regarded  this  variable  as  an 
unofficial primary endpoint. We had decided to look at this 
variable from the start, because we regarded it as being more 
relevant from our point of view, as we were most curious to 
see whether there is a biological response to PTH in human 
fracture healing (based on our previous experience with ani-
mals). The sponsor, however, was forced to concentrate on 
healing time because it was regarded as being more closely 
related to clinical application by the American Food and Drug 
Administration. 
In contrast to the the main study, our sub-study showed a 
tendency to a more prominent effect in the high-dose PTH 
group.  As  the  main  study  examined  cortical  bridging,  its 
results might be sensitive to increased remodeling during the 
later stages of healing, so that the higher PTH dose may have 
made  the  forming  cortex  less  visible  on  radiographs. This 
would be less of a problem during early healing.
Our study was mainly concerned with the effects of PTH on 
human fracture repair. It was not our primary goal to improve 
the clinical outcome. In the main study, few differences were 
seen between the treatment groups concerning grip strength 
and function, using PRWE (patient-related wrist evaluation 
score). There were no differences regarding palmar and radial 
displacement angles, but both PTH groups showed less radial 
shortening than the placebo group (p = 0.01). However, the 
combination of these results indicates that the clinical value 
of PTH treatment on distal radial fractures, if there is any, is 
limited. 
Several drugs are currently being tested for improvement of 
fracture repair, but there is still no consensus regarding which 
outcome variables should be used. Radiography has (at most) 
a moderate relation to clinical outcome; also, if radiography 
has been chosen, it is unclear whether one should take mea-
surements at a single time point or measure the time to the 
occurrence of some criterion for healing. Although teripara-
tide had an influence on both the appearance of the callus at 
5 weeks and the time to cortical continuity, the correlation 
between callus rating at 5 weeks and healing times was not 
impressive. This may reflect the fact that the two evaluation 
methods measure different aspects of healing. A strong early 
callus response—in this case at 5 weeks—is possibly the more 
important of the two.
We are reporting our subgroup results to help somewhat in 
the ongoing discussions both about the use of PTH and about 
radiographic outcome criteria. We are aware that the correct 
approach would have been to first confirm our findings with 
a repeat study, with a protocol for qualitative assessment at 5 
weeks. Still, our data add to the picture of the possible useful-
ness of PTH for fracture repair in general. 
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